-
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2020/09/17/US20200291039A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200291039A1
公开(公告)日：2020-09-17
申请号：US16890663
申请日：2020-06-02
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors](/abs-image/US/2020/08/04/US10730880B2/abs.jpg.150x150.jpg)
公开(公告)号：US10730880B2
公开(公告)日：2020-08-04
申请号：US16212493
申请日：2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2020/06/02/US10669269B2/abs.jpg.150x150.jpg)
13.发明授权公开(公告)号：US10669269B2
公开(公告)日：2020-06-02
申请号：US15717700
申请日：2017-09-27
Applicant: ARRAY BIOPHARMA INC.
Inventor： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsäter , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC: A61K31/496 , A61K45/06 , C07D471/04
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
-
公开(公告)号：US10125134B2
公开(公告)日：2018-11-13
申请号：US15814279
申请日：2017-11-15
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Jay Bradford Fell , John P. Fischer , John J. Gaudino , Erik James Hicken , Ronald Jay Hinklin , Matthew Randolf Lee , Matthew Arnold Marx , Macedonio J. Mejia , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P. A. Vigers , Henry J. Zecca
IPC: C07D471/04 , C07D519/00 , A61K31/519
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
![SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS](/abs-image/US/2016/01/07/US20160002232A1/abs.jpg.150x150.jpg)
15.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 有权取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-羧酰胺化合物作为III型受体酪氨酸激酶抑制剂公开(公告)号：US20160002232A1
公开(公告)日：2016-01-07
申请号：US14858029
申请日：2015-09-18
Applicant: ARRAY BIOPHARMA INC.
Inventor： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC: C07D471/04 , A61K45/06 , A61K31/496
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06
Abstract: Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Abstract translation: 用于治疗哺乳动物纤维化，骨相关疾病，癌症，自身免疫疾病，炎性疾病，心血管疾病，疼痛和灼伤的化合物。
-
Patent Agency Ranking
公开(公告)号：US08895550B2
公开(公告)日：2014-11-25
申请号：US14054459
申请日：2013-10-15
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , Robert Kirk DeLisle , Julie Marie Hicks , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao
IPC: A61K31/437 , A61K31/4353 , C07D471/04
CPC classification number: C07D471/04
Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.
Abstract translation: 本文提供了通过向有需要的哺乳动物施用治疗有效量的式I化合物来治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病的方法：其中B，R1， R1a，R2，R3，R4，R5，R6，R7，R10和R11具有说明书中给出的含义。
-
公开(公告)号：US11932633B2
公开(公告)日：2024-03-19
申请号：US17053273
申请日：2019-05-06
Applicant: Mirati Therapeutics, Inc. , Array BioPharma, Inc.
Inventor： Matthew Arnold Marx , Matthew Randolph Lee , James F. Blake , Mark Joseph Chicarelli , Jay Bradford Fell , John P. Fischer , Erik James Hicken , Pavel Savechenkov , Tony Tang , Guy P. A. Vigers , Henry J. Zecca
IPC: C07D413/06 , A61P35/00 , C07D413/04 , C07D413/14 , C07D417/14
CPC classification number: C07D413/14 , A61P35/00 , C07D413/06
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
![Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors](/abs-image/US/2023/12/05/US11834453B2/abs.jpg.150x150.jpg)
公开(公告)号：US11834453B2
公开(公告)日：2023-12-05
申请号：US17362580
申请日：2021-06-29
Applicant: Array BioPharma Inc.
Inventor： Mark Laurence Boys , Bryan Daniel Ellis , John Joseph Gaudino , Erik James Hicken , Ellen Ruth Laird , Nicholas Charles Lazzara , Bradley Jon Newhouse , Spencer Phillip Pajk
IPC: A61K31/519 , C07D487/04 , A61K45/06 , C07D519/00
CPC classification number: C07D487/04 , A61K45/06 , C07D519/00
Abstract: This invention relates to compounds of Formula (I):
and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.-
公开(公告)号：US11634409B2
公开(公告)日：2023-04-25
申请号：US17745346
申请日：2022-05-16
Applicant: Array BioPharma Inc.
Inventor： Patrick Michael Barbour , Katie Keaton Brown , Adam Wade Cook , Erik James Hicken , Dean Russell Kahn , Ellen Ruth Laird , Andrew Terrance Metcalf , David Austin Moreno , Bradley Jon Newhouse , Spencer Phillip Pajk , Brett Joseph Prigaro , Li Ren , Eugene Tarlton
IPC: C07D403/12 , C07D239/90 , C07D239/91 , A61K31/4184 , A61K45/06
Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
-
公开(公告)号：US20210380570A1
公开(公告)日：2021-12-09
申请号：US17053273
申请日：2019-05-06
Applicant: Mirati Therapeutics, Inc. , Array BioPharma, Inc.
Inventor： Matthew Arnold Marx , Matthew Randolph Lee , James F. Blake , Mark Joseph Chicarelli , Jay Bradford Fell , John P. Fischer , Erik James Hicken , Pavel Savechenkov , Tony Tang , Guy P.A. Vigers , Henry J. Zecca
IPC: C07D413/14 , C07D413/06 , A61P35/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.047 seconds)
